The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study)
Open accessAbstract
Objective: Friedreich ataxia (FA) is a progressive genetic neurodegenerative disorder with no approved treatment. Omaveloxolone, an Nrf2 activator, improves mitochondrial function, restores redox balance, and reduces inflammation in models of FA. We investigated the safety and efficacy of omaveloxolone in patients with FA. Methods: We conducted an international, double‐blind, randomized, placebo‐controlled, parallel‐group, registrational phase 2 trial at 11 institutions in the United States, Europe, and Australia (NCT02255435, EudraCT2015‐002762‐23). Eligible patients, 16 to 40 years of age with genetically confirmed FA and baseline modified Friedreich's Ataxia Rating Scale (mFARS) scores between 20 and 80, were randomized 1:1 to placebo or 150mg per day of omaveloxolone. The primary outcome was change from baseline in the mFARS score in those treated with omaveloxolone compared with those on placebo at 48 weeks. Results: One hundred fifty‐five patients were screened, and 103 were randomly assigned to receive omaveloxolone (n = 51) or placebo (n = 52), with 40 omaveloxolone patients and 42 placebo patients analyzed in the full analysis set. Changes from baseline in mFARS scores in omaveloxolone (−1.55 ± 0.69) and placebo (0.85 ± 0.64) patients showed a difference between treatment groups of –2.40 ± 0.96 (p = 0.014). Transient reversible increases in aminotransferase levels were observed with omaveloxolone without increases in total bilirubin or other signs of liver injury. Headache, nausea, and fatigue were also more common among patients receiving omaveloxolone. Interpretation: In the MOXIe trial, omaveloxolone significantly improved neurological function compared to placebo and was generally safe and well tolerated. It represents a potential therapeutic agent in FA. ANN NEUROL 2021;89:212–225
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dinkova-Kostova, A. T., Liby, K. T., Stephenson, K. K., Holtzclaw, W. D., Gao, X., Suh, N., Williams, C., Risingsong, R., Honda, T., Gribble, G. W., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500815102 · Cited by 569
The past and present of serum aminotransferases and the future of liver injury biomarkers
McGill, M. R. (2016) · EXCLI journal · doi:10.17179/excli2016-800 · Cited by 487
Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin
Koutnikova, H., Campuzano, V., Foury, F., Dollé, P., Cazzalini, O., & Koenig, M. (1997) · Nature Genetics · doi:10.1038/ng0897-345 · Cited by 474
Sookoian, S., & Pirola, C. J. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i3.711 · Cited by 344
Mortality in Friedreich Ataxia
Tsou, A. Y., Paulsen, E. K., Lagedrost, S. J., Perlman, S. L., Mathews, K. D., Wilmot, G. R., Ravina, B., Koeppen, A. H., & Lynch, D. R. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.05.023 · Cited by 315
Self-citationImpaired Nuclear Nrf2 Translocation Undermines the Oxidative Stress Response in Friedreich Ataxia
Paupe, V., Dassa, E. P., Goncalves, S., Auchère, F., Lönn, M., Holmgren, A., & Rustin, P. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004253 · Cited by 218
Measuring Friedreich ataxia: Complementary features of examination and performance measures
Lynch, D. R., Farmer, J. M., Tsou, A. Y., Perlman, S., Subramony, S. H., Gomez, C. M., Ashizawa, T., Wilmot, G. R., Wilson, R. B., & Balcer, L. J. (2006) · Neurology · doi:10.1212/01.wnl.0000218155.46739.90 · Cited by 210
Self-citationPandolfo, M. (2008) · Archives of Neurology · doi:10.1001/archneur.65.10.1296 · Cited by 206
Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia
Lynch, D. R., Farmer, J., Hauser, L., Blair, I. A., Wang, Q. Q., Mesaros, C., Snyder, N., Boesch, S., Chin, M., Delatycki, M. B., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.660 · Cited by 173
Self-citationNovel Nrf2-Inducer Prevents Mitochondrial Defects and Oxidative Stress in Friedreich’s Ataxia Models
Abeti, R., Baccaro, A., Esteras, N., & Giunti, P. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00188 · Cited by 165
Self-citation
Cited by
Advances and challenges in therapeutic targeting of NRF2
Dinkova-Kostova, A. T., & Copple, I. M. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.12.003 · Cited by 266
Sun, Y., Xu, L., Zheng, D., Wang, J., Liu, G., Mo, Z., Liu, C., Zhang, W., Yu, J., Xing, C., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102793 · Cited by 54
Cuadrado, A., Cazalla, E., Bach, A., Bathish, B., Naidu, S. D., DeNicola, G. M., Dinkova-Kostova, A. T., Fernández-Ginés, R., Grochot-Przeczek, A., Hayes, J. D., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103569 · Cited by 28
Metadata
- Authors
- Lynch, D. R., Chin, M. P., Delatycki, M. B., Subramony, S. H., Corti, M., Hoyle, J. C., Boesch, S., Nachbauer, W., Mariotti, C., Mathews, K. D., Giunti, P., Wilmot, G., Zesiewicz, T., Perlman, S., Goldsberry, A., O'Grady, M., & Meyer, C. J.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2020-11-05
- Volume
- 89
- Issue
- 2
- Pages
- 212-225
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W3092673148
- Cited by
- 332
- References
- 30
- FWCI
- 11.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study). https://app.cochat.ai/papers/10.1002/ana.25934
- The paper
- Lynch, D. R., Chin, M. P., Delatycki, M. B., Subramony, S. H., Corti, M., Hoyle, J. C., Boesch, S., Nachbauer, W., Mariotti, C., Mathews, K. D., Giunti, P., Wilmot, G., Zesiewicz, T., Perlman, S., Goldsberry, A., O'Grady, M., & Meyer, C. J. (2021). Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study). Annals of Neurology. https://doi.org/10.1002/ana.25934
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.